Introduction
Diabetes mellitus is a growing disease largely accounted for an increasing number of people diagnosed with Type 2 diabetes mellitus (T2D M ). In the Netherlands, treat-ment of T2D M is often started by a general practitioner (GP). Changing lifestyle and dietary measures are usually the first step. The second step is pharmacotherapy with an oral blood glucose-lowering drug. In the early 1990s in the Netherlands, as in the rest of the world, there were three groups of oral blood glucose-lowering drugs available, i.e. biguanides, sulphonylureas and αglucosidase-inhibitors. After 1999, two new groups of drugs, i.e. meglitinides (repaglinide, nateglinide) and thiazolidinediones (rosiglitazone, pioglitazone), became available.
International and national guidelines provide evidence-based recommendations for the treatment of TD2M [1] . In the Netherlands, we have national practice guidelines of the Dutch College of General Practitioners (NHG) [2, 3] . The first NHG guideline for T2D M appeared in 1989 and recommended to start with a short-acting (or weak) sulphonylurea, such as tolbutamide, in all T2D M patients. When the effect of tolbutamide was insufficient, a switch was recommended to a longer-acting (strong) sulphonylurea, such as gliclazide or glibenclamide. The use of metformin was reserved for obese patients with a body mass index (BMI) > 30 kg m − 2 . The biguanide metformin was feared for its risk of lactic acidosis and considered to be contraindicated in patients with renal impairment or cardiovascular complications. The α -glucosidase-inhibitors were judged to be modestly effective, but hampered by a high prevalence of gastrointestinal side-effects and recommended only in combination with other drugs.
In September 1998, the United Kingdom Prospective Diabetes Study (UKPDS) research group published the results of intensified treatment of diabetes and demonstrated the beneficial effects of metformin in overweight T2D M patients [4, 5] . Worldwide, the UKPDS results changed the existing ideas of treating T2D M . In 1999, the NHG guideline was thoroughly revised in line with the results of the UKPDS study. In the revised guideline, a distinction in pharmacological treatment was made for patients with a BMI above and below 27 kg m − 2 [3] . Lean patients (BMI < 27 kg m − 2 ) were advised to start initial treatment with a sulphonylurea, such as tolbutamide or gliclazide. For obese patients (BMI ≥ 27 kg m − 2 ) the recommendation was to start with metformin. When monotherapy failed, a combination of metformin and sulphonylurea was considered appropriate. The new drugs, meglitinides and thiazolidinediones, were not yet included in this revised guideline.
It is recognized that new guidelines or insights are not always implemented in daily practice [6, 7] . From studies of drug prescription trends conducted in the USA and UK, it has become clear that the use of metformin and thiazolidinediones has increased since 1997 at the expense of especially long-acting sulphonylurea [8] [9] [10] [11] . These studies, however, did not provide insight into the treatment steps at the level of the individual patient. Therefore, it is not clear to what extent these drugs were prescribed as initial or follow-up treatment. In this study, we investigated the impact of revised insights and guidelines on the prescription trends for initial treatment of T2D M patients as well as for the treatment changes during follow-up.
Methods
The InterAction Database (IADB), containing pharmacy dispensing data from 53 community pharmacies in the Northern and Eastern part of the Netherlands, was used in this study [12, 13] . In the period from 1997 to 2003, the IADB covered a population of approximately 450 000 people. The size of this population increased over the study period but there was no change in age and gender distribution. In the Netherlands, people commonly register with one pharmacy and obtain all their medication from that pharmacy, so that a complete medication history of an individual is available in the pharmacy dispensing records.
The prevalence and incidence rates of oral antihyperglycaemic drug use (ATC code A10B*, Table 1 ) were calculated per year according to age group ( ≤ 14 years, 15-39 years, 40-64 years, ≥ 65 years) and gender. The yearly prevalence rate was calculated by counting the number of patients receiving one or more prescriptions for an oral antihyperglycaemic drug divided by the total number of patients in the database per age and gender group in the respective years. The incidence rate of oral antihyperglycaemic drug use was defined as the number of people who received initial treatment with an oral antihyperglycaemic drug per year.
From the population, we defined patients using antihyperglycaemic drugs as patients being treated for T2D M . In this group, proportions of initial treatment were calculated for every calendar year of the observation period. Initial treatment was defined as the first prescription dispensed for an antihyperglycaemic drug when no antihyperglycaemic drugs had been dispensed in the preceding 6 months (in the Netherlands, drugs are dispensed for a maximum of 3 months). When a patient received two prescriptions for antihyperglycaemic drugs at the date of the initial treatment both prescriptions were counted. χ 2 tests were used to determine differences between proportions.
To investigate changes in treatment during follow-up, we followed two cohorts of initial users over a period of 2.7 years (1000 days). The first cohort started an oral antihyperglycaemic drug in 1998 and the second cohort in 2000, one year before and one year after, respectively, the introduction of the revised NHG guidelines. The cohorts were divided into those starting with metformin (initial metformin group) and those starting with a sulphonylurea (initial sulphonylurea group). The cohorts were separately evaluated for males and females. Data were analysed using Kaplan-Meier survival (log-rank tested) and Cox proportional hazard analyses. The event in these analyses was the start of another antihyperglycaemic drug (metformin, sulphonylurea or insulin), either in addition to or as a replacement of the initial drug. Survival time was censored for death or moving (loss to follow-up) and follow-up period. Adjustments for age differences (between the cohorts) were made using Cox proportional hazard analyses. All statistical analyses were performed using SPSS 12 statistical software (SPSS Inc., Chicago, IL, USA).
Results
The prevalence and incidence rate of oral antihyperglycaemic drug use increased in the study period (Table 2 , Figure 1A ,B). The prevalence rate increased from 1.8% to 2.4% ( P < 0.001) and this change was similar for males and females ( Table 2 ). The incidence rate increased from 0.3% to 0.4% ( P = 0.04). The incidence and prevalence rate for the very young ( < 15 years) was almost zero, and not displayed.
The proportion of metformin as initial treatment showed a large increase from 13.4% in 1998 to 49.9% in 2003 (Figure 2 , P < 0.001), consequently decreasing the proportion of initial sulphonylurea use. Of the sulphonylureas, the use of gliclazide and glimepiride was unchanged, whereas that of glibenclamide and tolbutamide decreased. The use of other drugs, including acarbose, rosiglitazon, pioglitazon, repaglinide and insulin, was very small as initial treatment. Finally, between 2 and 3% of the patients were given two different antihyperglycaemic drugs as initial treatment.
After 2.7 years, 39% of the patients on initial sulpho- nylurea treatment had received follow-up treatment with metformin, whereas 52% of initial metformin users had received follow-up treatment with sulphonylurea. In 20-38% of the patients on initial metformin treatment, follow-up treatment with a sulphonylurea was already started within the first 100 days ( Figure 3A,C) , whereas follow-up treatment with metformin was more gradual over the whole study period (Figure 3B,D) . Especially females in the 2000 cohort on initial metformin treatment were less likely to receive sulphonylurea in the follow-up period compared with the 1998 cohort (Figures 3C, P = 0.003). In both year cohorts, 10% of the males and 25% of the females discontinued using metformin after receiving follow-up treatment with a sulphonylurea, which could not be attributed to any differences in prescribed dosages of metformin (data not shown). The initial users of sulphonylurea in the 2000 cohort were more likely to receive metformin compared with the 1998 cohort ( P = 0.007). No difference was found between males and females ( Figure 3B,D) . In 10% of the cases, the sulphonylurea was discontinued after follow-up treatment with metformin was started.
Age differences between the cohorts were only small and did not influence the differences found.
At the end of the follow-up period, about 8% of the initial metformin and initial sulphonylurea users had started with insulin (data not shown). No earlier switch to insulin was found between the year or gender cohorts, but there was a difference in discontinuation rates of the initial drug. After receiving insulin, more patients discontinued using the sulphonylurea (70%) compared with metformin (40%) ( P < 0.05).
Discussion
Based on pharmacy dispensing data, we found an increase in the prevalence and incidence rate of oral antihyperglycaemic drug use over the period [1998] [1999] [2000] [2001] [2002] [2003] . Changes in initial and follow-up prescription rates of individual drugs were largely in agreement with new insights and revised treatment recommendations. The percentage of T2D M patients on initial treatment with metformin increased from 15% in 1998 to 50% in 2003. Furthermore, metformin was added more frequently to initial sulphonylurea treatment in 2000 compared with 1998. The new drugs, thiazolidinediones and meglitinides, were seldom used as initial treatment.
Several studies have addressed changes in pharmacological treatment in diabetes over time. Some did not focus on specific drug treatments [14, 15] , included all diabetes mellitus patients [9] or were based on data from the early 1990s [15] [16] [17] . Those that did address treatment changes in the period during and after the publi- cation of the main UKPDS results showed that metformin use increased after 1997 [8] [9] [10] [11] . Our study demonstrates that the rapid increase in metformin use was largely due to the increased use of metformin as initial treatment but also as follow-up treatment for patients started on sulphonylurea, which is in accordance with the revised guideline recommendations in the Netherlands. The fact that the new drugs, marketed after 2000, and α -glucosidase-inhibitors were hardly prescribed as initial treatment is also in agreement with the guideline recommendations. It can, however, be expected that the extension of the registered indications of the thiazolidinediones in Europe in 2004, allowing their use as monotherapy in T2D M patients, will lead to an increased use of these drugs as initial treatment. This is analogous to the USA, where thiazolidinediones were marketed earlier and had a broader registration at introduction, and where a steep increase in their prescription rates has been reported [8, 11] . Within the group of the sulphonylureas, the prescription of glibenclamide and tolbutamide decreased during the study period. Only the decreased use of glibenclamide is in accordance with the revised guidelines and corresponds with observations in the UK that longeracting sulphonylureas are increasingly being replaced by shorter-acting drugs [9, 10] .
The observation that female patients discontinued metformin more frequently than male patients when receiving follow-up treatment with sulphonylurea is intriguing. We observed no differences in prescribed male  male  1998 75  42  40  31  28  456  375  324  280  243  2000 130  83  70  60  52  436  338  281  232  195   1998 78  48  39  33  27  551  442  389  327  382  2000 169  125  112  94  85  491  365  304 dosages for metformin between males and females. The discontinuation rate in females of 25% is much larger than expected from tolerability data of clinical trials, which showed that 10-15% of patients discontinued metformin because of adverse effects [18] . A strength of this study is that the pharmacy dispensing records were linked to individual patients. This made it possible to follow individual drug use over time. Prevalence data give insight only into the percentage of the population exposed to oral antihyperglycaemic drugs in a given period of time. The incidence and follow-up prescription rates give a better insight into the drug preferences of doctors in specific time periods.
Patients at risk
The use of a pharmacy dispensing database also has its limitations . Pharmacy databases do not include detailed clinical information. Therefore, it is not known whether the observed prescription rates for metformin fully followed the revised guideline with respect to the prevailing BMI. On the other hand, the proportion of metformin users corresponds to the estimated 60% of T2D M patients that have a BMI > 27 kg m − 2 in the Netherlands [19, 20] .
Second, we recognize that there is a small overlap between the two year cohorts, which tends to result in an underestimation.
In conclusion, we found a significant change in the prescribing pattern of oral antihyperglycaemic drugs in patients with T2DM which was in concordance with the publication of the UKPDS results and practice guideline revisions in the Netherlands. This indicates that in this therapeutic area changes in insights and treatment recommendations were quickly transferred into daily clinical practice.
